CN116172172A - Fig microcapsule powder capable of improving intestinal motility abnormality and preparation method thereof - Google Patents
Fig microcapsule powder capable of improving intestinal motility abnormality and preparation method thereof Download PDFInfo
- Publication number
- CN116172172A CN116172172A CN202211671254.7A CN202211671254A CN116172172A CN 116172172 A CN116172172 A CN 116172172A CN 202211671254 A CN202211671254 A CN 202211671254A CN 116172172 A CN116172172 A CN 116172172A
- Authority
- CN
- China
- Prior art keywords
- microcapsule powder
- fruit
- grinding
- dietary fiber
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 129
- 239000003094 microcapsule Substances 0.000 title claims abstract description 95
- 230000008991 intestinal motility Effects 0.000 title claims abstract description 40
- 230000005856 abnormality Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 104
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 58
- 238000000227 grinding Methods 0.000 claims abstract description 55
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 15
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims abstract description 15
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims abstract description 15
- 102000004139 alpha-Amylases Human genes 0.000 claims abstract description 13
- 108090000637 alpha-Amylases Proteins 0.000 claims abstract description 13
- 229940024171 alpha-amylase Drugs 0.000 claims abstract description 13
- 108091005508 Acid proteases Proteins 0.000 claims abstract description 12
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 5
- 230000002378 acidificating effect Effects 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- 239000011324 bead Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 238000004537 pulping Methods 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- 238000007710 freezing Methods 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 7
- 239000000834 fixative Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 6
- 230000009849 deactivation Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000004945 emulsification Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 235000013305 food Nutrition 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 37
- 210000001072 colon Anatomy 0.000 description 18
- 239000000203 mixture Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 230000002159 abnormal effect Effects 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 235000013824 polyphenols Nutrition 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 description 9
- 210000000813 small intestine Anatomy 0.000 description 9
- 239000000084 colloidal system Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000003995 emulsifying agent Substances 0.000 description 8
- 230000002550 fecal effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000012661 Dyskinesia Diseases 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000013872 defecation Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- -1 polyphenol compounds Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960004192 diphenoxylate Drugs 0.000 description 3
- 230000003636 fecal output Effects 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000503 bisacodyl Drugs 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IKGXLCMLVINENI-QOXGANSBSA-M [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC Chemical compound [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC IKGXLCMLVINENI-QOXGANSBSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000009384 kangtai Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960002088 pinaverium bromide Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses fig microcapsule powder capable of improving intestinal motility abnormality and a preparation method thereof, and belongs to the technical field of foods. The fig microcapsule powder is fig fruit microcapsule powder or fig fruit residue dietary fiber microcapsule powder; the fig fruit microcapsule powder is prepared by microencapsulating fig pulp by utilizing gamma-cyclodextrin, homogenizing, emulsifying and grinding; the fig pomace dietary fiber microcapsule powder is obtained by respectively carrying out enzymolysis on fig pomace under an acidic condition by alpha-amylase and acid protease. The fig fruit microcapsule powder and the fig fruit residue dietary fiber microcapsule powder can effectively improve intestinal motility abnormality.
Description
Technical Field
The invention relates to the technical field of foods, in particular to fig microcapsule powder capable of improving intestinal motility abnormality and a preparation method thereof.
Background
Intestinal motility disorder is a common gastrointestinal function problem, causes of intestinal motility disorder are complex, and involves including colon, small intestine and other digestive tract motility disorder, even external digestive tract motility disorder, and intestinal motility disorder has a very serious influence on life health condition of human. Intestinal dyskinesia is clinically manifested as diarrhea, constipation, or a mixture of both, and symptoms occur from young to old, but the prevalence in the elderly is relatively high, and intestinal dyskinesia can also lead to a variety of complications. Intestinal dyskinesia also occurs in children, and although conventional treatments are effective in most children, few symptoms persist. Intestinal motility abnormalities are usually accompanied by lesions in the morphology of colon tissue, mainly associated with irregular villus alignment, reduced muscle layer thickness, crypt damage, inflammatory cell infiltration, and also result in increased permeability of the intestinal and blood brain barriers. Generally, drugs with irritation or permeability are used for treating intestinal motility disorders, such as pinaverium bromide tablets, bisacodyl drugs and the like, but the problems of strong dependence and high recurrence rate of the drugs can occur when the drugs are used, and the side effects of allergy, stomachache and the like can also occur after the patients use the drugs, so that the clinical application of the drugs for relieving intestinal motility disorders is limited. Compared with therapeutic drugs, the regulation of intestinal homeostasis by food and natural active ingredients using food sources has a positive role in the treatment of intestinal dysmotility, and is also a research hotspot in recent years. The former has demonstrated that fig polysaccharide has a promoting effect on intestinal motility and thus can effectively improve intestinal motility abnormality.
The fig is a fruit with higher nutritive value, and the fig fruit is rich in polysaccharide, polyphenol, vitamins, minerals, dietary fibers and other nutritive substances, and can adsorb substances in the gastrointestinal tract which are harmful to human bodies after being eaten, so that the fig has a purifying effect on the intestinal tract, provides a better growth environment for beneficial microorganisms and promotes proliferation. The research shows that the polyphenol has antioxidant activity in intestinal tracts, can influence the expression of inflammatory factors, antioxidant enzymes and barrier proteins, can effectively improve the oxidative stress of the intestinal tracts and the impaired barrier function of the intestinal tracts, and can maintain the steady state of the intestinal tracts. The natural polyphenol in the plants has the effects of anti-inflammation, anti-tumor, blood fat reduction, oxidation resistance and the like, can effectively prevent various chronic diseases, can reduce the risk of metabolic disturbance when being eaten by foods and drinks rich in the polyphenol, has outstanding bacteriostatic activity, and can be used as a good natural preservative.
But fig is a quaternary fruit which is quick in ripening and aging, is not storage-resistant, has a short fresh eating period and is extremely easy to rot and deteriorate. At present, less research is conducted on fig processing, and the fig is mainly directly processed into dried fruits, fruit juice, cans or fruit powder. These rough processing means result in a significant loss of nutrients in the fig, which is not fully utilized in the fig's nutritional value.
Disclosure of Invention
Aiming at the problems, the invention discloses fig microcapsule powder capable of improving intestinal motility abnormality and a preparation method thereof. The invention divides the whole fig fruit into fruit and pomace, and uses microencapsulation technique and vacuum freeze drying technique to the fruit; and preparing dietary fiber by a dry method by fruit residues. Effectively reduces the loss and damage of fig nutrients and has the effect of improving intestinal motility abnormality.
The first object of the invention is to provide the fig microcapsule powder for improving intestinal motility abnormality, wherein the fig microcapsule powder is fig fruit microcapsule powder or fig fruit dreg dietary fiber microcapsule powder;
the fig fruit microcapsule powder is prepared by microencapsulating fig pulp by utilizing gamma-cyclodextrin, homogenizing, emulsifying and grinding;
the fig pomace dietary fiber microcapsule powder is obtained by respectively carrying out enzymolysis on fig pomace under an acidic condition by alpha-amylase and acid protease.
The second object of the present invention is to provide a preparation method of the fig microcapsule powder for improving intestinal motility abnormality, which comprises the following steps:
step 1, selecting mature fresh fig fruits, adding a color fixative and distilled water, mixing and pulping, wherein the ratio of the fresh fig fruits to the distilled water is 1g to 1.5-2 mL, pulping, sieving, and separating into fig pulp and fig pomace;
step 2, preparing the fig fruit microcapsule powder
S2.1, adding gamma-cyclodextrin into the fig pulp for microencapsulation, and grinding to obtain grinding liquid;
s2.2, homogenizing and emulsifying the grinding fluid to obtain a homogenized fluid, pre-freezing the homogenized fluid, and freeze-drying to obtain fig pulp dry powder;
s2.3, adding the fig pulp dry powder and the agate beads according to the weight ratio of 1:8-12, and grinding for 2-3 times at the rotating speed of 280-320 r/min for 30-50 min each time to obtain fig fruit microcapsule powder;
step 3, preparing fig fruit residue dietary fiber microcapsule powder
S3.1, adding water into the fig pomace, and then carrying out enzymolysis by using alpha-amylase and acid protease; after enzyme deactivation, centrifuging, filtering, pre-freezing and freeze-drying to obtain fig pomace dietary fiber dry powder;
s3.2, adding the fig fruit residue dietary fiber dry powder and agate beads according to the weight ratio of 1:3-5, and grinding to obtain the fig fruit residue dietary fiber microcapsule powder.
Preferably, in the step 1, the color fixative is sodium tripolyphosphate, and the addition amount of the color fixative is 0.4-0.6% of the mass of fresh fig fruits.
Preferably, in S2.1, the addition amount of the gamma-cyclodextrin is 10-20% of the mass of the fig pulp, and the grinding times are 1-3.
Preferably, in S2.2, the caprylic acid glyceride is added for emulsification, the addition amount of the caprylic acid glyceride is 1-2% of the mass of the grinding fluid, and the homogenization times are 3-5 times.
Preferably, in S3.1, after adding water into the fig pomace, adding alpha-amylase, treating for 70-100 min at 55-70 ℃ and pH value of 5.6-6.6, adding acid protease, and treating for 50-80 min at 40-60 ℃ and pH value of 2.5-3.5;
wherein, the addition ratio of fig fruit residues to water is 1g: 15-20 ml; the addition amount of the alpha-amylase is 0.3-1.0% of the mass of the fig pomace, and the addition amount of the acid protease is 0.3-1.0% of the mass of the fig pomace.
Preferably, in S3.2, the grinding step is to grind the fig fruit residue dietary fiber microcapsule powder by a ball mill for 30-50 min and 5-8 times at the rotating speed of 280-320 r/min.
Preferably, in S2.2, pre-freezing is carried out for 12-14 hours at the temperature of minus 80 ℃ and vacuum freeze drying is carried out for 36-48 hours;
the pre-freezing and freeze-drying process of S3.1 is the same as that of S2.2.
Compared with the prior art, the invention has the following beneficial effects:
(1) The fig is innovatively utilized to improve intestinal motility abnormality, so that the nutritional ingredients in the fig are effectively utilized;
(2) The process can effectively avoid the loss of polyphenol substances in the preservation process of the figs, and effectively retain the polyphenol compounds in the figs; the dietary fiber modification can effectively retain dietary fiber in fig pomace, so that the fig pomace has the function of remarkably improving intestinal motility abnormality and colon tissue injury;
(3) The fig powder prepared by the process is moderate in particle size and uniform in distribution;
(4) The fig fruit microcapsule powder and the fig fruit residue dietary fiber microcapsule powder prepared by the invention can effectively improve the defecation condition of the mice with abnormal intestinal motility, can also effectively enhance the intestinal creep capacity of the mice with abnormal intestinal motility, increase the thickness of colon muscle layers, improve the depth of crypt and relieve the injury of colon tissues under the condition of abnormal intestinal motility. And has the characteristics of stable quality and storage resistance.
Drawings
FIG. 1 is a gallic acid standard curve of total phenols of fig fruit microcapsule powder.
Fig. 2 (a) is the defecation amount of 3 hours of mice taking fig fruit microcapsule powder and fig pomace dietary fiber microcapsule powder, and fig. 2 (b) is the water content of the feces of mice taking fig fruit microcapsule powder and fig pomace dietary fiber microcapsule powder.
FIG. 3 shows the intestinal tract propulsion rate of mice taking fig fruit microcapsule powder and fig pomace dietary fiber microcapsule powder.
FIG. 4 is a photograph of H & E staining of the colon of a mouse (black arrow part indicates muscle thickness), control: healthy control group (a); model: model control group (b); bisacoyl: a positive drug control group (c); UFPD: a group of fig fruit microcapsule powders (d); DF: a group of fig pomace dietary fiber microcapsule powder (e); scale bar: 100. Mu.M.
Fig. 5 is a colon pathology evaluation of mice, fig. 5 (a) is colon muscle thickness of mice taking fig fruit microcapsule powder and fig pomace dietary fiber microcapsule powder, and fig. 5 (b) is colon crypt depth of mice taking fig fruit microcapsule powder and fig pomace dietary fiber microcapsule powder.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications. The reagents or equipment used are not manufacturer specific and conventional products can be purchased by regular vendors.
Example 1
(1) Mature fresh fig fruits are selected, sodium tripolyphosphate with the mass of 0.5% of that of the fresh fig fruits is added for color protection, distilled water is added for mixing and pulping, the ratio of material to water is controlled at 1:1.5 (g: mL), and the pulp is sieved by a 80-mesh sieve after pulping, and the pulp and the residue are separated into fine fig pulp and fig pomace.
(2) And (3) adding gamma-cyclodextrin into the fine fig pulp for microencapsulation, wherein the adding amount is 17% of the weight of the fine fig pulp, and grinding the fine fig pulp for 2 times (2 min/time) by a colloid mill to obtain grinding liquid.
(3) Adding 1.5% of the weight of the grinding fluid into the mixture to serve as an emulsifier, and homogenizing the mixture for 3 times to obtain a homogenized solution.
(4) And (3) pre-freezing the homogenized solution in a refrigerator at the temperature of minus 80 ℃ for 12 hours, and carrying out vacuum freeze drying at the temperature of minus 56.4 ℃ for 36 hours, and fully drying to obtain the fig pulp dry powder.
(5) Grinding the fig pulp dry powder and agate beads according to a weight ratio of 1:10 by a ball mill at a rotating speed of 300r/min for 30min for 2 times to obtain the fig fruit microcapsule powder.
(6) Adding water into the fig pomace, and treating with 0.4% alpha-amylase at 60 ℃ and pH value of 6.0 for 80min under the condition that the feed-liquid ratio is 1:15 (g: mL). Treating with 0.4% acid protease at 50deg.C and pH of 3.0 for 60min. After enzyme deactivation at 100 ℃,4200r/min is centrifuged, filtered, pre-frozen and vacuum freeze-dried to obtain the fig residue dietary fiber dry powder.
(7) Grinding the fig fruit residue dietary fiber dry powder and agate beads according to a weight ratio of 1:3 by a ball mill at a rotating speed of 300r/min for 40min for 6 times to obtain the fig fruit residue dietary fiber microcapsule powder.
Example 2
Steps (4) and (6) are the same as in example 1.
(1) Mature fresh fig fruits are selected, sodium tripolyphosphate with the mass of 0.5% of that of the fresh fig fruits is added for color protection, distilled water is added for mixing and pulping, the ratio of material to water is controlled at 1:2 (g: mL), and the pulp is sieved by a 40-mesh sieve after pulping, and the pulp and the residue are separated into fine fig pulp and fig pomace.
(2) And (3) adding gamma-cyclodextrin into the fine fig pulp for microencapsulation, wherein the adding amount is 10% of the weight of the fine fig pulp, and grinding the fine fig pulp for 2 times (2 min/time) by a colloid mill to obtain grinding liquid.
(3) Adding 1% of the weight of the ground slurry into the mixture to serve as an emulsifier, and homogenizing the mixture for 3 times to obtain a homogenized solution.
(5) Grinding the fig pulp dry powder and agate beads according to the weight ratio of 1:10 by a ball mill at the rotating speed of 280r/min for 30min for 2 times to obtain the fig fruit microcapsule powder.
(7) Grinding the fig fruit residue dietary fiber dry powder and agate beads according to the weight ratio of 1:3 by a ball mill at the rotating speed of 280r/min for 30min for 5 times to obtain the fig fruit residue dietary fiber microcapsule powder.
Example 3
Steps (1), (4) and (6) are the same as in example 1.
(2) And (3) adding gamma-cyclodextrin into the fine fig pulp for microencapsulation, wherein the adding amount is 14% of the weight of the fine fig pulp, and grinding the fine fig pulp for 2 times (2 min/time) by a colloid mill to obtain grinding liquid.
(3) Adding the caprylin and the caprin which are 1.2 percent of the weight of the ground slurry as an emulsifying agent, and homogenizing for 4 times to obtain a homogenized solution.
(5) Grinding the fig pulp dry powder and agate beads according to the weight ratio of 1:10 by a ball mill at the rotation speed of 290r/min for 35min for 2 times to obtain the fig fruit microcapsule powder.
(7) Grinding the fig fruit residue dietary fiber dry powder and agate beads according to the weight ratio of 1:3 by a ball mill at the rotation speed of 290r/min for 35min for 6 times to obtain the fig fruit residue dietary fiber microcapsule powder.
Example 4
Steps (1), (4) and (6) are the same as in example 1.
(2) And (3) adding gamma-cyclodextrin into the fine fig pulp for microencapsulation, wherein the adding amount is 17% of the weight of the fine fig pulp, and grinding the fine fig pulp for 2 times (2 min/time) by a colloid mill to obtain grinding liquid.
(3) Adding the caprylin and the caprin which are 1.5 percent of the weight of the ground slurry as an emulsifying agent, and homogenizing for 5 times to obtain a homogenized solution.
(5) Grinding the fig pulp dry powder and agate beads according to a weight ratio of 1:10 by a ball mill at a rotating speed of 300r/min for 40min for 3 times to obtain the fig fruit microcapsule powder.
(7) Grinding the fig fruit residue dietary fiber dry powder and agate beads according to a weight ratio of 1:3 by a ball mill at a rotating speed of 300r/min for 40min for 6 times to obtain the fig fruit residue dietary fiber microcapsule powder.
Example 5
Steps (1), (4) and (6) are the same as in example 1.
(2) And (3) adding gamma-cyclodextrin into the fine fig pulp for microencapsulation, wherein the adding amount is 18% of the weight of the fine fig pulp, and grinding the fine fig pulp for 2 times (2 min/time) by a colloid mill to obtain grinding liquid.
(3) Adding the caprylin and the caprin which are 1.8 percent of the weight of the ground slurry as an emulsifying agent, and homogenizing for 3 times to obtain a homogenized solution.
(5) Grinding the fig pulp dry powder and agate beads according to the weight ratio of 1:10 by a ball mill at the rotating speed of 310r/min for 50min for 3 times to obtain the fig fruit microcapsule powder.
(7) Grinding the fig fruit residue dietary fiber dry powder and agate beads according to the weight ratio of 1:3 by a ball mill at the rotating speed of 310r/min for 50min for 7 times to obtain the fig fruit residue dietary fiber microcapsule powder.
Example 6
Steps (1), (4) and (6) are the same as in example 1.
(2) And (3) adding gamma-cyclodextrin into the fine fig pulp for microencapsulation, wherein the adding amount is 20% of the weight of the fine fig pulp, and grinding the fine fig pulp for 2 times (2 min/time) by a colloid mill to obtain grinding liquid.
(3) Adding 2% of the weight of the ground slurry into the mixture to serve as an emulsifier, and homogenizing the mixture for 5 times to obtain a homogenized solution.
(5) Grinding the fig pulp dry powder and agate beads according to the weight ratio of 1:10 by a ball mill at the rotating speed of 320r/min for 50min for 3 times to obtain the fig fruit microcapsule powder.
(7) Grinding the fig fruit residue dietary fiber dry powder and agate beads according to the weight ratio of 1:3 by a ball mill at the rotating speed of 320r/min for 50min for 8 times to obtain the fig fruit residue dietary fiber microcapsule powder.
Example 7
(1) Mature fresh fig fruits are selected, sodium tripolyphosphate with the mass of 0.4% of that of the fresh fig fruits is added for color protection, distilled water is added for mixing and pulping, the ratio of material to water is controlled at 1:1.7 (g: mL), and the pulp is sieved by a 80-mesh sieve after pulping, and the pulp and the residue are separated into fine fig pulp and fig pomace.
(2) And (3) adding gamma-cyclodextrin into the fine fig pulp for microencapsulation, wherein the adding amount is 17% of the weight of the fine fig pulp, and grinding the fine fig pulp for 1 time (2 min/time) by a colloid mill to obtain grinding liquid.
(3) Adding 1.5% of the weight of the grinding fluid into the mixture to serve as an emulsifier, and homogenizing the mixture for 3 times to obtain a homogenized solution.
(4) And (3) pre-freezing the homogenized solution in a refrigerator at the temperature of minus 80 ℃ for 14 hours, and carrying out vacuum freeze drying at the temperature of minus 56.4 ℃ for 48 hours, and fully drying to obtain the fig pulp dry powder.
(5) Grinding the fig pulp dry powder and agate beads according to the weight ratio of 1:8 by a ball mill at the rotating speed of 300r/min for 30min for 2 times to obtain the fig fruit microcapsule powder.
(6) Adding water into the fig pomace, and treating with 0.3% alpha-amylase at 55 ℃ and pH value of 5.6 for 70min under the condition that the feed-liquid ratio is 1:20 (g: mL). Treating with 0.3% acid protease at 40deg.C and pH of 2.5 for 50min. After enzyme deactivation at 100 ℃,4200r/min is centrifuged, filtered, pre-frozen and vacuum freeze-dried to obtain the dry powder of the fruit residue dietary fiber.
(7) Grinding the fig fruit residue dietary fiber dry powder and agate beads according to a weight ratio of 1:4 by a ball mill at a rotating speed of 300r/min for 40min for 6 times to obtain the fig fruit residue dietary fiber microcapsule powder.
Example 8
(1) Mature fresh fig fruits are selected, sodium tripolyphosphate with the mass of 0.6% of that of the fresh fig fruits is added for color protection, distilled water is added for mixing and pulping, the ratio of material to water is controlled at 1:2 (g: mL), and the mixture is sieved by a 80-mesh sieve after pulping and is separated into fine fig pulp and fig pomace.
(2) And (3) adding the fine fig pulp into gamma-cyclodextrin for microencapsulation, wherein the adding amount is 17% of the weight of the fine fig pulp, and grinding the fine fig pulp for 3 times (2 min/time) by a colloid mill to obtain grinding liquid.
(3) Adding 1.5% of the weight of the grinding fluid into the mixture to serve as an emulsifier, and homogenizing the mixture for 3 times to obtain a homogenized solution.
(4) And (3) pre-freezing the homogenized solution in a refrigerator at the temperature of minus 80 ℃ for 13 hours, and carrying out vacuum freeze drying at the temperature of minus 56.4 ℃ for 40 hours, and fully drying to obtain the fig pulp dry powder.
(5) Grinding the fig pulp dry powder and agate beads according to a weight ratio of 1:12 by a ball mill at a rotating speed of 300r/min for 30min for 2 times to obtain the fig fruit microcapsule powder.
(6) Adding water into the fig fruit residue, and treating with 1.0% alpha-amylase at 70deg.C and pH of 6.6 for 100min at a feed-liquid ratio of 1:18 (g: mL). Treating with 1.0% acid protease at 60deg.C and pH of 3.5 for 80min. After enzyme deactivation at 100 ℃,4200r/min is centrifuged, filtered, pre-frozen and vacuum freeze-dried to obtain the dry powder of the fruit residue dietary fiber.
(7) Grinding the fig fruit residue dietary fiber dry powder and agate beads according to a weight ratio of 1:5 by a ball mill at a rotating speed of 300r/min for 40min for 6 times to obtain the fig fruit residue dietary fiber microcapsule powder.
Test example 1 determination of functional Components of fig fruit microcapsule powder
The tests were divided into fig raw fruit groups and fig fruit microcapsule powder groups (example 1), and the total phenol content was determined by the forskolin-phenol method. The gallic acid standard curve is drawn by taking absorbance (A) as an ordinate and gallic acid concentration (c) as an abscissa, and the result is shown in figure 1. The linear relationship is y=105.79x+0.0242, r 2 = 0.9919, linearity is good. The total phenol content results are shown in Table 1.
TABLE 1 functional ingredients of fig fruit micro-capsule powder
By measuring the total phenol content of the fig original fruits and the fig fruit microcapsule powder, the total phenol content of the fig fruits subjected to supermolecule microencapsulation is close to the total phenol content of the fig original fruits, and the fig fruits have no obvious difference. The microencapsulation embedding can effectively retain polyphenol substances in the fig pulp, and the protection rate reaches 74.1 percent. Related researches show that the drying mode can cause the loss of the polyphenol active substances of the figs, and few reports on the protection mode of the polyphenol substances exist, so that the method can effectively embed the polyphenol substances in the figs.
Test example 2 measurement of fig pomace dietary fiber micro-capsule powder
The invention utilizes alpha-amylase and acid proteinase to prepare the fig fruit residue dietary fiber by an enzyme method, and obtains the fruit residue dietary fiber microcapsule powder (example 1) by vacuum freeze drying and dry modification of dietary fiber technology, wherein the fig fruit residue dietary fiber microcapsule powder is light brown, uniform in powder form and free of peculiar smell. The total dietary fiber mass of the fig fruit residue dietary fiber microcapsule powder is 52.6% of the total fruit residue by the national standard method GB 5009.88-2014.
Test example 3 Effect of fig microcapsule powder on intervention in intestinal dyskinesia mouse model
1. Materials and methods
1.1 test materials
Test animals: 8-week-old female BALB/c mice with a weight of 18-20 g are taken as study subjects, and 4 mice are fed into a unified cage, are fed in a stable environment (the temperature is 22+/-2 ℃ and the humidity is 50+/-5%), and are fed with maintenance feed, and the illumination/darkness duration is 12 hours. Animal test groups were as follows: (1) healthy Control group (Control, n=10), (2) Model Control group (Model, n=10), (3) positive drug Control group (bisacosyl, n=10), (4) fig fruit microcapsule powder (example 1) group, (UFPD, n=10), (5) fig fruit residue dietary fiber microcapsule powder (example 1) group (DF, n=10)
Reagent: compound diphenoxylate (H32022716, division of the pharmaceutical industry, hedzhou compu); bisacodyl enteric coated tablet (H13022092, hebei Kangtai pharmaceutical Co., ltd.).
1.2 establishing a model of intestinal dyskinesia
After 14d of adaptive feeding, intervention of micro-capsule powder (UFPD, 1.5 mg/g) of fig fruits, micro-capsule powder (DF, 1 mg/g) of dietary fibers of fig pomace and Bisacode (positive control, 0.1 mg/g) is carried out for 21d, and meanwhile, the healthy control group and the model control group are filled with pure water, and the gastric lavage amount is 0.1mL/10g each time. After the gastric lavage for 14d, intestinal motility abnormality models were established for mice of other groups except the healthy control group by using 5mg/kg of compound diphenoxylate for gastric lavage for 7 d. After 7d of dosing modeling, each group of mice was fasted without water withdrawal for 16h, and then the mice were sacrificed to detect each index. The body weight, the food intake and the water intake of the mice are detected every 3 days, and the follow-up analysis is carried out.
1.3 detection of faecal Condition
After modeling, fresh feces of the mice were taken daily, and the feces moisture content was measured (Faecal water content, FWC). Transferring the mice to clean beakers respectively, collecting 0.1-0.2 g of fresh feces from each mouse, immediately placing the mice into a 1.5mL dry centrifuge tube for collection, and weighing; the feces were baked to constant weight in a 105℃incubator and weighed. The calculation formula is as follows: fecal moisture content (%) = [ fresh fecal mass (g) -dry fecal mass (g) ]/fresh fecal mass (g) ×100. And 19d, performing pure water gastric lavage on the healthy control group mice, and performing 5mg/kg of compound diphenoxylate gastric lavage on the model control group mice and the intervention group mice. After 20 minutes, each mouse was transferred to a separate, clean, non-padded cage. Fecal particles were collected every 1 hour and weighed immediately, 3 times per mouse. The 3h Faecal displacement (FO) was calculated for each group of mice.
1.4 intestinal motility detection
All mice were fasted for 16h without water withdrawal prior to sacrifice. Each mouse is prepared by dissolving 10g of gum arabic powder in 80mL of pure water, boiling until the mixture becomes transparent, adding 5g of active carbon powder, stirring, boiling for 3 times, naturally cooling to room temperature, adding water, mixing to constant volume to 100mL, placing in a refrigerator at 4deg.C for standby), pouring stomach, removing neck, sacrificing after 30min, cutting the abdomen of the mouse, taking out the whole small intestine part on clear mesh paper, measuring the whole small intestine length and ink pushing length, and calculating intestinal tract pushing rate (IPR). The calculation formula is as follows: intestinal tract thrust (%) = ink thrust length/small intestine total length×100.
1.5H & E staining of colon tissue
After the mice are sacrificed, the colon tissues which are taken out and about 0.5cm are put into 4% (v/v) paraformaldehyde/PBS fixing solution for 24 hours for fixation, the mice are dehydrated by alcohol with different concentrations and then are immersed in wax for embedding, the embedded wax blocks are cut into slices with the size of 5-8 mu m, and the slices are dried in a constant-temperature oven at 45 ℃ after being fished. Placing the slice into xylene for dewaxing; the paraffin sections of the colon tissue were dewaxed and rehydrated sequentially with ethanol at a concentration gradient from 100% to 75%. Staining with hematoxylin aqueous solution; color separation in glacial acetic acid and dilute ammonia water; washing with distilled water for 1h; dehydrating in 70% and 90% alcohol for 10min. And (3) dyeing the alcohol eosin staining solution for 2-3 min. After staining, ethanol was dehydrated, and then treated with xylene for transparency, gum was fixed, and after observation by a microscope, colon tissue was quantitatively analyzed by Image J software.
1.6 statistical analysis
All experiments were repeated 3 times and the experimental data were expressed as Mean ± standard deviation (Mean ± SD). p <0.05 indicates that the difference is significant, and p <0.01 indicates that the difference is extremely significant. Significance analysis was performed using GraphPad Prism 9.0, analysis of variance was tested using One-WayANOVA, turkey. The histopathological pictures are subjected to Image processing and quantitative analysis by adopting Image J software.
2. Test results
2.1 influence of fig microcapsule powder on mouse weight
Initial body weight, final body weight, food intake, and water intake index of each group of mice were monitored, as shown in table 2.
TABLE 2 weight status of mice
The results show that the fig fruit microcapsule powder and the fig fruit residue dietary fiber microcapsule powder can not cause abnormal weight of the mice, and have no obvious adverse effect on the health state of the mice.
2.2 influence of fig microcapsule powder on bowel movement abnormal model mice defecation condition
The intestinal motility abnormal mice were assayed for 3h fecal output and fecal moisture content, and the results are shown in figure 2. The model group showed a significant decrease in both fecal output and fecal water content (p < 0.01) for 3h compared to the control group, indicating successful establishment of the intestinal dysmotility model. The fecal output of mice after intervention was significantly increased (p < 0.05) in the bisacosyl group and DF group compared to the model group, and the fecal water content was significantly increased (p < 0.01) in the bisacosyl group, UFPD group and DF group compared to the model group. The results show that the fig fruit microcapsule powder can improve the problem of dry stool of mice with abnormal intestinal motility, and the intervention of the fig fruit residue dietary fiber microcapsule powder can effectively improve the conditions of difficult defecation and dry stool of the mice with abnormal intestinal motility.
2.3 influence of fig microcapsule powder on intestinal motility of mice with abnormal intestinal motility model
Small Intestine Propulsion Rate (IPR) is an important measure of intestinal motility, and the results are shown in fig. 3. The small intestine fraction was significantly reduced in the model group compared to the control group (p < 0.01). Compared with the model group, the small intestine propulsion rate of the UFPD group is obviously increased (p < 0.05), the small intestine propulsion rate of the Bisacode group and the DF group is extremely obviously increased (p < 0.01). The results show that the small intestine propulsion rate of the mice with abnormal intestinal motility can be effectively improved by the intervention of the fig microcapsule powder.
2.4 influence of fig microcapsule powder on colon tissue morphology of mice with intestinal dysmotility model
The colon tissue was subjected to H & E staining to analyze the colon histopathological changes of the mice, and the results are shown in FIG. 4. The quantitative analysis results (fig. 5) show that the colon muscle thickness of the mice in the model group is significantly reduced (p < 0.01) and the crypt depth is significantly shortened (p < 0.01) compared with the control group. The muscle thickness after the intervention of the UFPD group and the DF group is obviously improved compared with the model group (p < 0.01). The recess depth was significantly increased (p < 0.01) after the UFPD group and DF group interventions compared to the model group. The results show that the fig microcapsule powder intervention can effectively improve colon tissue injury of the mice with abnormal intestinal motility.
While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. It is therefore intended that the following claims be interpreted as including the preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention also include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (8)
1. The fig microcapsule powder for improving intestinal motility abnormality is characterized by being prepared from fig fruit microcapsule powder or fig fruit residue dietary fiber microcapsule powder;
the fig fruit microcapsule powder is prepared by microencapsulating fig pulp by utilizing gamma-cyclodextrin, homogenizing, emulsifying and grinding;
the fig pomace dietary fiber microcapsule powder is obtained by respectively carrying out enzymolysis on fig pomace under an acidic condition by alpha-amylase and acid protease.
2. A method for preparing the fig microcapsule powder for improving intestinal motility disorder according to claim 1, which is characterized by comprising the following steps:
step 1, selecting mature fresh fig fruits, adding a color fixative and distilled water, mixing and pulping, wherein the ratio of the fresh fig fruits to the distilled water is 1g to 1.5-2 mL, pulping, sieving, and separating into fig pulp and fig pomace;
step 2, preparing the fig fruit microcapsule powder
S2.1, adding gamma-cyclodextrin into the fig pulp for microencapsulation, and grinding to obtain grinding liquid;
s2.2, homogenizing and emulsifying the grinding fluid to obtain a homogenized fluid, pre-freezing the homogenized fluid, and freeze-drying to obtain fig pulp dry powder;
s2.3, adding the fig pulp dry powder and the agate beads according to the weight ratio of 1:8-12, and grinding for 2-3 times at the rotating speed of 280-320 r/min for 30-50 min each time to obtain fig fruit microcapsule powder;
step 3, preparing fig fruit residue dietary fiber microcapsule powder
S3.1, adding water into the fig pomace, and then carrying out enzymolysis by using alpha-amylase and acid protease; after enzyme deactivation, centrifuging, filtering, pre-freezing and freeze-drying to obtain fig pomace dietary fiber dry powder;
s3.2, adding the fig fruit residue dietary fiber dry powder and agate beads according to the weight ratio of 1:3-5, and grinding to obtain the fig fruit residue dietary fiber microcapsule powder.
3. The preparation method of the fig microcapsule powder for improving intestinal motility disorder according to claim 2, wherein in the step 1, the color fixative is sodium tripolyphosphate, and the addition amount of the color fixative is 0.4-0.6% of the mass of fresh fig fruits.
4. The preparation method of the fig microcapsule powder for improving intestinal motility disorder according to claim 2, wherein in S2.1, the addition amount of the gamma-cyclodextrin is 10% -20% of the mass of the fig pulp, and the grinding times are 1-3 times.
5. The preparation method of the fig microcapsule powder for improving intestinal motility disorder according to claim 2, wherein in S2.2, caprylin-caprin is added for emulsification, the addition amount of the caprylin-caprin is 1-2% of the mass of the grinding fluid, and the homogenization times are 3-5.
6. The method for preparing the fig microcapsule powder for improving intestinal motility disorder according to claim 2, wherein in S3.1, after adding water into fig pomace, adding alpha-amylase, treating for 70-100 min at 55-70 ℃ and pH of 5.6-6.6, adding acid protease, and treating for 50-80 min at 40-60 ℃ and pH of 2.5-3.5;
wherein, the addition ratio of fig fruit residues to water is 1g: 15-20 ml; the addition amount of the alpha-amylase is 0.3-1.0% of the mass of the fig pomace, and the addition amount of the acid protease is 0.3-1.0% of the mass of the fig pomace.
7. The preparation method of the fig microcapsule powder for improving intestinal motility disorder according to claim 2, wherein in S3.2, the grinding step is carried out by ball mill grinding at the rotation speed of 280-320 r/min for 30-50 min and 5-8 times to obtain the fig fruit residue dietary fiber microcapsule powder.
8. The method for preparing the fig microcapsule powder for improving intestinal motility disorder according to claim 2, wherein in S2.2, prefreezing is performed at-80 ℃ for 12-14 h, and vacuum freeze drying is performed for 36-48 h;
the pre-freezing and freeze-drying process of S3.1 is the same as that of S2.2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211671254.7A CN116172172A (en) | 2022-12-26 | 2022-12-26 | Fig microcapsule powder capable of improving intestinal motility abnormality and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211671254.7A CN116172172A (en) | 2022-12-26 | 2022-12-26 | Fig microcapsule powder capable of improving intestinal motility abnormality and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116172172A true CN116172172A (en) | 2023-05-30 |
Family
ID=86437518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211671254.7A Pending CN116172172A (en) | 2022-12-26 | 2022-12-26 | Fig microcapsule powder capable of improving intestinal motility abnormality and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116172172A (en) |
-
2022
- 2022-12-26 CN CN202211671254.7A patent/CN116172172A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102960644B (en) | Preparation method of pumpkin dietary fiber and pumpkin dietary fiber | |
CN101203270B (en) | Substances having body mass redistribution properties | |
CN111671765B (en) | Application of brown algae dietary fiber in preparation of medicines, foods and/or health care products for treating or preventing metabolic syndrome | |
CN114832022B (en) | Preparation of Phellinus linteus fruiting body phenol active substances and application thereof in regulating intestinal flora and uric acid metabolism | |
CN112007057A (en) | Preparation method of wall-broken ganoderma lucidum spore powder capsule and wall-broken ganoderma lucidum spore powder capsule | |
CA2871478C (en) | Pleuropterus multiflorus extract and dipsacus asperoides extract for stimulating the secretion of insulin-like growth factor and promoting bone structure growth, and method for preparing same | |
CN106667915A (en) | Baicalin-aluminum dry suspension for treating pigling diarrhoea | |
WO1999025197A1 (en) | Fenugreek compositions having reduced taste and odor and methods of use | |
CN107865930A (en) | A kind of pine pollen composition and its preparation method and application | |
CN110559352A (en) | hawthorn flavone microcapsule and preparation method and application thereof | |
CN103815015B (en) | A kind of production method of medlar bud coarse cereals functional yoghourt | |
US10799547B2 (en) | Composition comprising suaeda japonica for preventing or alleviating diabetes | |
KR20170036886A (en) | A method of preparing beverage using pear, stone cell and strawberry | |
CN116172172A (en) | Fig microcapsule powder capable of improving intestinal motility abnormality and preparation method thereof | |
CN105713942B (en) | Broccoli polypeptide active component and preparation method thereof and application | |
CN114377160A (en) | Preparation method of larch arabinogalactan composition | |
CN113973986B (en) | New application of pithecaria clypearia extract and poultry feed | |
CN110664785B (en) | Hawthorn flavone microcapsule and preparation method and application thereof | |
CN105111328B (en) | A kind of preparation method of the luxuriant mushroom polysaccharide of selenic acid esterification shuttle handle pine | |
CN113768123A (en) | Betel nut core extract and preparation method and application thereof | |
CN104256847B (en) | A kind of efficient defecation method of cider | |
CN114081893A (en) | Application of combined anthocyanin and pectin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease | |
CN109021135A (en) | A kind of codonopsis pilosula var. modesta polysaccharide formulation and preparation method thereof | |
KR102440573B1 (en) | Composition for Prebiotics Containing Poly-Gamma-Glutamate | |
CN110558556A (en) | preparation method of royal jelly acid microcapsule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |